A Brief Overview of The History of The Development of Pharmacological Antihypertensive Therapy

For many decades, cardiovascular diseases have been the leading cause of death worldwide. There is evidence that the total number of cardiovascular diseases has doubled over the past 30 years, and the number of deaths from them has steadily increased by 65 % over the same time. At the same time, the increasing prevalence of arterial hypertension as the most important risk factor for cardiovascular diseases is a global problem for world health. In this situation, the issue of antihypertensive therapy and its quality is relevant. There is still a need for further research into new classes of antihypertensive drugs. The article briefly discusses the evolution of views on the pathogenesis of arterial hypertension, the gradual introduction of drugs that lower blood pressure into widespread clinical practice. The article also presents new groups of drugs and the latest trends in the treatment of arterial hypertension.

1. Booth J. A short history of blood pressure measurement. Proc R SocMed. 1977;70(11):793-799.

2. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):1269-1324. doi: 10.1161/HYP.0000000000000066

3. Fogelson L.I. Diseases of the heart and blood vessels. M.: State Publishing House of Biological and Medical Literature; 1935 ; 120 р. [in Russian].

4. Pletnev D.D. Hypertension (experience of analyzing its genesis). Pulmonologiya. 2022; 32 (2, Suppl.): 22–26. doi: 10.18093/0869-0189-2022-32-2S-22-26 [in Russian].

5. Lang G.F. Hypertension. L.: Medgiz; 1950; 353 р. [in Russian].

6. Azimov A. A brief history of chemistry /Trans. from English V.M. Abashkina. M.: ZAO Tsentrpoligraf; 2002; 106 р. [in Russian].

7. Glazer G, Myers KA, Davies ER. Ergot poisoning. Postgrad Med J. 1966;42(491):562-568. doi: 10.1136/pgmj.42.491.562

8. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensinconverting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [published correction appears in JAMA 2003 Jan 8;289(2):178] [published correction appears in JAMA. 2004 May 12;291(18):2196]. JAMA. 2002;288(23):2981-2997. doi: 10.1001/jama.288.23.2981

9. Nikolic K, Agbaba D. Imidazoline antihypertensive drugs: selective i(1) -imidazoline receptors activation. Cardiovasc Ther. 2012;30(4):209-216. doi: 10.1111/j.1755-5922.2011.00269.x

10. Epinephrin from the Suprarenal Capsule: “A Classic of Science.” (1932). The Science News-Letter, 22(610), 391–392. doi: 10.2307/3908203

11. Powell CE, Slater IH. Blocking of inhibitory adrenergic receptors by a dichloro analog of isoproterenol. J Pharmacol Exp Ther. 1958;122(4):480-488.

12. Black JW, Crowther AF, Shanks RG, Smith LH, Dornhorst AC. A new adrenergic betareceptor antagonist. Lancet. 1964;1(7342):1080-1081. doi: 10.1016/s0140-6736(64)91275-9

13. Frishman W.H., Charlap S. Alpha-and beta-adrenergic blocking drugs //Cardiovascular Pharmacotherapeutics. New York, NY: McGraw-Hill. 2003; 67-97.

14. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A metaanalysis. Lancet. 2005;366(9496):1545-1553. doi: 10.1016/S0140-6736(05)67573-3

15. Hollman A. Plants in cardiology. BMJ, 1992. 40. doi: 10.1136/hrt.67.5.376

16. SoRelle R. Withdrawal of Posicor from market. Circulation. 1998;98(9):831-832. doi: 10.1161/01.cir.98.9.831

17. Friedel HA, Brogden RN. Pinacidil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension. Drugs. 1990;39(6):929-967. doi: 10.2165/00003495-199039060-00008

18. Stevens CD, Kotte JH. The treatment of human hypertension with a kidney extract. Am J Med Sci. 1946;211:227-231.

19. Page, Taylor, Corcoran a. others. Correlation of clinical types of hypertension with renal function. Ill. Effect of spinal anaesthesia. J. A. M. A., 124, 185, 1944.

20. Ferreira SH. A Bradykinin-potentiating factor (bpf) present in the venom of bothrops jararca. Br J Pharmacol Chemother. 1965;24(1):163-169. doi: 10.1111/j.1476-5381.1965.tb02091.x

21. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet. 2000;355(9204):637-645. doi: 10.1016/s0140-6736(99)10365-9

22. Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367(23):2204-2213. doi: 10.1056/NEJMoa1208799

23. Богданов Д.В., Шишминцева Е.П. Особенности терапии артериальной гипертензии на врачебном участке. Медицинская наука и образование Урала. 2023. Т.24,№ 1; 11-14. doi: 10.36361/18148999_2023_24_1_11 Bogdanov DV, Shishmintseva EP. Peculiarities of therapy of arterial hypertension in the medical site. Medical science and education of Ural. 2023. Vol.24, no.1; 11-14. doi: 10.36361/18148999_2023_24_1_11 [in Russian].

24. Williams B, Cockcroft JR, Kario K, et al. Effects of Sacubitril/ Valsartan Versus Olmesartan on Central Hemodynamics in the Elderly With Systolic Hypertension: The PARAMETER Study. Hypertension. 2017;69(3):411-420. doi: 10.1161/HYPERTENSIONAHA.116.08556

25. Roth GA, Mensah GA, Johnson CO, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study [published correction appears in J Am Coll Cardiol. 2021 Apr 20;77(15):1958-1959. doi: 10.1016/j.jacc.2021.02.039.]. J Am Coll Cardiol. 2020;76(25):2982-3021. doi: 10.1016/j.jacc.2020.11.010

26. Dogra S, Shah S, Gitzel L, et al. Baxdrostat: A Novel Aldosterone Synthase Inhibitor for Treatment Resistant Hypertension. Curr Probl Cardiol. 2023;48(11):101918. doi: 10.1016/j.cpcardiol.2023.101918

27. Bakris GL, Saxena M, Gupta A, et al. RNA Interference With Zilebesiran for Mild to Moderate Hypertension: The KARDIA-1 Randomized Clinical Trial. JAMA. 2024;331(9):740-749. doi: 10.1001/jama.2024.0728

28. Freeman MW, Halvorsen YD, Marshall W, et al. Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension. N Engl J Med. 2023;388(5):395-405. doi: 10.1056/NEJMoa2213169

29. Trensz F, Bortolamiol C, Kramberg M, et al. Pharmacological Characterization of Aprocitentan, a Dual Endothelin Receptor Antagonist, Alone and in Combination with Blockers of the Renin Angiotensin System, in Two Models of Experimental Hypertension. J Pharmacol Exp Ther. 2019;368(3):462-473. doi: 10.1124/jpet.118.253864